General Neoadjuvant atezolizumab addition quadruples pathological responses in resectable lung tumorsBy Healthcare Propulsion StaffSeptember 12, 20260 Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median…
